Raymond James & Associates’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-796
| Closed | -$13.8K | – | 3967 |
|
|
2024
Q1 | $13.8K | Buy |
796
+12
| +2% | +$213 | ﹤0.01% | 3892 |
|
|
2023
Q4 | $10K | Sell |
784
-6,802
| -90% | -$159K | ﹤0.01% | 3792 |
|
|
2023
Q3 | $281K | Buy |
7,586
+92
| +1% | +$4.09K | ﹤0.01% | 3256 |
|
|
2023
Q2 | $302K | Sell |
7,494
-62
| -0.8% | -$3.51K | ﹤0.01% | 3255 |
|
|
2023
Q1 | $548K | Buy |
7,556
+287
| +4% | +$27.8K | ﹤0.01% | 2868 |
|
|
2022
Q4 | $596K | Sell |
7,269
-105
| -1% | -$10.9K | ﹤0.01% | 2778 |
|
|
2022
Q3 | $697K | Buy |
7,374
+4,765
| +183% | +$535K | ﹤0.01% | 2615 |
|
|
2022
Q2 | $508K | Buy |
+2,609
| New | +$426K | ﹤0.01% | 2907 |
|
|
2020
Q2 | – | Sell |
-951
| Closed | -$202K | – | 3526 |
|
|
2020
Q1 | $202K | Buy |
951
+104
| +12% | +$33K | ﹤0.01% | 3038 |
|
|
2019
Q4 | $349K | Buy |
847
+38
| +5% | +$13.1K | ﹤0.01% | 2985 |
|
|
2019
Q3 | $286K | Sell |
809
-9
| -1% | -$3.36K | ﹤0.01% | 3036 |
|
|
2019
Q2 | $411K | Sell |
818
-218
| -21% | -$154K | ﹤0.01% | 2812 |
|
|
2019
Q1 | $1.03M | Buy |
1,036
+7
| +0.7% | +$6.5K | ﹤0.01% | 2179 |
|
|
2018
Q4 | $893K | Sell |
1,029
-12
| -1% | -$11.1K | ﹤0.01% | 2150 |
|
|
2018
Q3 | $1.08M | Sell |
1,041
-15
| -1% | -$14.7K | ﹤0.01% | 2209 |
|
|
2018
Q2 | $970K | Sell |
1,056
-61
| -5% | -$65.5K | ﹤0.01% | 2240 |
|
|
2018
Q1 | $1.09M | Buy |
1,117
+104
| +10% | +$94.8K | ﹤0.01% | 2076 |
|
|
2017
Q4 | $458K | Buy |
1,013
+69
| +7% | +$25.5K | ﹤0.01% | 2585 |
|
|
2017
Q3 | $391K | Hold |
944
| – | – | ﹤0.01% | 2628 |
|
|
2017
Q2 | $330K | Buy |
944
+132
| +16% | +$50.9K | ﹤0.01% | 2662 |
|
|
2017
Q1 | $417K | Buy |
812
+91
| +13% | +$37.7K | ﹤0.01% | 2495 |
|
|
2016
Q4 | $256K | Buy |
+721
| New | +$305K | ﹤0.01% | 2742 |
|
Other funds holding ATRA
RG
EC
BC
CC
VPC